People: Compugen Ltd (CGEN.PH)

CGEN.PH on Philadelphia Stock Exchange

5.35USD
24 May 2013
Price Change (% chg)

$-0.08 (-1.47%)
Prev Close
$5.43
Open
$5.35
Day's High
$5.35
Day's Low
$5.35
Volume
100
Avg. Vol
--
52-wk High
--
52-wk Low
--

Search Stocks

Summary

Name Age Since Current Position

Martin Gerstl

 71 2010 Chairman of the Board

Anat Cohen-Dayag

 44 2010 President, Chief Executive Officer

Dikla Czaczkes

 38 2008 Chief Financial Officer & Investor Relations Contact

Zurit Levine

 44 2011 Vice President - Research and Discovery

Eyal Neria

 48 2011 Vice President of Therapeutic Development

Dov Hershberg

 72 2010 Director

Alex Kotzer

 65 2008 Director

Yair Aharonowitz

 71 2007 Independent External Director

Ruth Arnon

 79 2007 Independent Director

Arie Ovadia

 64 2007 Independent External Director

Joshua Shemer

 62 2007 Independent External Director
» Insider Trading

Biographies

Name Description

Martin Gerstl

 Mr. Martin S. Gerstl serves as Chairman of the Board of Directors of Compugen Ltd. He has served as Compugen’s Chairman of the board of directors since 1997, other than from February 2009 to February 2010, during which time he served as either CEO or co-CEO and, in both cases, as a member of the board of directors. Prior to Compugen, Mr. Gerstl was co-chairman and CEO of ALZA Corporation, which he helped found in 1968. Mr. Gerstl is the Chairman of Evogene Ltd., Keddem Bioscience, Mada Ltd., the co-founder and co-chairman of Itamar Medical, and serves as a director of Yissum Ltd., Yeda Ltd. and the U.S. Foundation for the National Medals of Science and Technology. He is a member of the Board of Governors and the Executive Committee of the Weizmann Institute of Science and the Board of Governors of The Hebrew University of Jerusalem, and is an advisor to the Burrill Life Science Funds and the board of the Israel-U.S. Binational Industrial Research and Development Foundation. Mr. Gerstl holds a B.S. from Yale University and an MBA from Stanford University.

Anat Cohen-Dayag

 Dr. Anat Cohen-Dayag, Ph.D., serves as President, Chief Executive Officer of Compugen Ltd. She joined Compugen in 2002 as Director of Diagnostics, a position she held until 2005 at which time she became Vice President Diagnostic Biomarkers, a position she held until January 2007. From January 2007 until November 2008, Dr. Cohen-Dayag served as Compugen’s Vice President, Biomarkers and Drug Targets, at which point she was appointed Vice President, Research and Development. In June 2009, Dr. Cohen-Dayag was appointed, together with Mr. Martin Gerstel, as co-Chief Executive Officer of Compugen. In March 2010, upon Mr. Gerstel’s election as Chairman of the board of directors, Dr. Cohen-Dayag was appointed as Compugen’s President and CEO. Prior to joining Compugen, she was head of research and development and member of the Executive Management at Mindsense Biosystems Ltd. Prior to Mindsense Biosystems, Dr. Cohen-Dayag served as a scientist at the R&D department of Orgenics. Dr. Cohen-Dayag holds a B.Sc. in Biology from the Ben-Gurion University, Israel, and an M.Sc. in Chemical Immunology and a Ph.D. in Cellular Biology, both from the Weizmann Institute of Science, Israel. Additionally, Dr. Cohen-Dayag is an external director of Ramot at Tel Aviv University Ltd.

Dikla Czaczkes

 Ms. Dikla Czaczkes serves as Chief Financial Officer and Investor Relations Contact at Compugen Ltd since August, 2008. Prior to her current position, Ms. Czaczkes served as Finance Director at the Company from March, 2002 until February, 2007. Before joining the Company, she was Chief Financial Officer of Packet Technologies Ltd., a mobile internet security hardware and software startup company and before that an Audit Manager at Ernst & Young, Israel. Ms. Czaczkes holds an MBA in Finance and a BA in Accounting and Economics, both from the Tel Aviv University. She is also a Certified Public Accountant in Israel.

Zurit Levine

 Dr. Zurit Levine, Ph.D., is Vice President - Research and Discovery of Compugen Ltd., since 2011. She joined Compugen in 1999 and held several positions in Compugen’s Research & Development. In 2004, she was appointed Director of Therapeutic Selection & Validation, which position she held until 2007 when she was appointed Director of Therapeutic Discovery. In 2009, she was appointed Executive Director of Research & Development. From January 2010 to August 2011, she held the position of Vice President, Research and Development. In August 2011 she was appointed Vice President, Research and Discovery. Dr. Levine holds a B.Sc. in Biology, an M.Sc. in Biochemistry and a Ph.D. in Biochemistry, all from the Tel Aviv University, Israel.

Eyal Neria

 Mr. Eyal Neria serves as Vice President of Therapeutic Development of Compugen Ltd., since August, 2011. He joined Compugen in 2010. Prior to joining Compugen, he was CEO of Capsutech and of Peptera Pharmaceuticals, Head of R&D at Prochon Biotech, and Vice President R&D of Mindset Biopharmaceuticals. Dr. Neria holds a B.SC. in Chemistry and Computer Science and a Ph.D. in Chemical Physics both from Tel Aviv University and was a postdoctoral research fellow at Harvard University.

Dov Hershberg

 Mr. Dov Hershberg serves as Director of Compugen Ltd. He was appointed as a member of the board of directors in February 2009, prior to which he served as a consultant to the board of directors. From February 2009 through February 2010, Mr. Hershberg served as Chairman of the board of directors. Mr. Hershberg previously managed the Israel-U.S. Binational Industrial Research and Development (“BIRD”) Foundation from 1997 through 2006. He is currently a founder and executive director of Powermat, a wireless electricity company. Prior to joining BIRD, Mr. Hershberg held various senior management positions in software development, marketing and sales. He was the founder and CEO, with colleagues from Stanford University, of Molecular Applications Group which created software in biomedical research. He spent eleven years at Digital Equipment Corporation in various senior management positions in product development, marketing and sales and worked as a mathematician in the Israeli Aircraft Industry. Mr. Hershberg holds graduate degrees in Mathematics, from the Hebrew University in Jerusalem, Israel and in Applied Mathematics and Operations Research from Columbia University in New York City.

Alex Kotzer

 Mr. Alex Kotzer serves as Director of Compugen Ltd., since December, 2008. He has been serving as a director of Compugen since September 2005. From September 2005and until December 2008 he served also as President and Chief Executive Officer of the Company. Since February, 2010, Mr. Kotzer has served as the CEO and Chairman of the Board of RegeneraPharma. Prior to joining Compugen, he served for twelve years at Serono (currently Merck Serono), a global biotechnology leader, headquartered in Switzerland. During his tenure at Serono, Mr. Kotzer held several senior positions, first as the Chief Executive Officer of InterPharm, Serono's Israeli affiliate and then after relocating to Switzerland, as Vice President of Biotechnology Manufacturing. Before joining Serono, he held a variety of managerial positions in the food and chemical industries. Mr. Kotzer received his B.Sc. in Chemical Engineering from the Technion, Israel Institute of Technology, of Haifa, Israel.

Yair Aharonowitz

 Prof. Yair Aharonowitz, Ph.D., serves as Independent External Director of Compugen Ltd., since July 2007. He is a Professor (Emeritus) of Microbiology and Biotechnology at Tel Aviv University (TAU). He was a visiting scientist at Oxford University, an Alberta Heritage Fellow at the University of Alberta, Edmonton, and a visiting professor at the Karolinska Institute and at the University of British Columbia. Professor Aharonowitz’s research interests include the molecular genetics and biosynthesis of antibiotics, molecular biology of microbial pathogens and the development of new targets for new antibiotics. He served as TAU Vice President and Dean for R&D (1997-2001), Chairman of the Department of Microbiology and Biotechnology and Chairman of the Institute of Biotechnology and served as a member of the TAU Executive Council. He served as the Chairman of Ramot Fund for Applied Research, as a member of TAU committee for strategic planning, on the TAU patent committee and was a member of the National Committee for Biotechnology. He is a Fellow of the American Academy of Microbiology and a member of the Israeli Society of Microbiology.

Ruth Arnon

 Prof. Ruth Arnon serves as Independent Director of Compugen Ltd., since May 2007. Formerly the Vice-President of the Weizmann Institute of Science (1988-1997), she is a noted immunologist, having joined the Institute in 1960. She served as Head of the Department of Chemical Immunology, Dean of the Faculty of Biology and Director of the Institute's MacArthur Center for Molecular Biology of Tropical Diseases. Along with Prof. Michael Sela, she developed Copaxone® a drug for the treatment of multiple sclerosis which is presently marketed worldwide. Prof. Arnon is a member of the Israel Academy of Sciences and presently serves as its President. She is an elected member of the European Molecular Biology Organization, served as President of the European Federation of Immunological Societies and as Secretary-General of the International Union of Immunological Societies. Her awards include the Robert Koch Prize in Medical Sciences, Spain's Jiminez Diaz Memorial Prize, France's Legion of Honor, the Hadassah World Organization's Women of Distinction Award, the Wolf Prize for Medicine, the Rothschild Prize for Biology, the Israel Prize and she received an Honorary Doctorate from Ben-Gurion University and from the Tel Aviv University. In addition, Prof. Arnon is the incumbent of the Paul Ehrlich Chair in Immunochemistry at the Weizmann Institute.

Arie Ovadia

 Dr. Arie Ovadia serves as Independent External Director at Compugen Ltd., since July, 2007. He advises Israeli companies on finance, accounting and valuations, and is a member of the board of directors of several corporations, including Israel Discount Bank, Strauss Ltd., Israel Petrochemical Industries, ViryaNet and Elron Electronic Industries Ltd. He has taught at New York University, Temple University and, in Israel, at Tel Aviv and Bradford Universities. Dr. Ovadia served as a member of the Israeli Accounting Board, and is a 14-year member of the Israel Securities Authority. Dr. Ovadia holds an undergraduate degree and an MBA from Tel Aviv University, and earned his Ph.D. in economics from the Wharton School at the University of Pennsylvania.

Joshua Shemer

 Prof. Joshua Shemer serves as Independent External Director at Compugen Ltd., since July, 2007. He is Full Professor of Medicine at the Tel Aviv University. In addition, he is the Chairman of Assuta Medical Centers in Israel and Deputy Chairman of the Board of Directors of Maccabi Healthcare Services in Israel. Prof. Shemer is a director of the Israeli center for medical technology assessment in healthcare in Gertner Institute, Tel Hashomer. Prof. Shemer is an Associate Editor at IMAJ and Harefuah, and a member of the Editorial Board of the International Journal of Technology Assessment in Health Care. Prof. Shemer teaches Medical Technology Management at the Faculty of Business Administration at Tel Aviv University. He was a member and former chairman of the National Public Committee for Updating the National List of Health Services in Israel and the National Council for Trauma of the Israeli Ministry of Health. Most recently, Prof. Shemer was the Director-General of Maccabi Healthcare Services. Prof. Shemer was formerly Director-General of the Ministry of Health and Surgeon General of the Israel Defense Forces Medical Corps. Prof. Shemer has published 5 books and more than 200 peer reviewed articles. Additionally, Prof. Shemer is an external director of El-Al Airlines. He is a graduate of the Hebrew University and Hadassah School of Medicine and Board certified in Internal Medicine in Israel.

Insider Trading

» Full list on Insider Trading
Search Stocks